Showing 5371-5380 of 9753 results for "".
- Study Reveals TikTok's Impact on Psoriasis Treatment Understandinghttps://practicaldermatology.com/news/study-reveals-tiktoks-impact-on-psoriasis-treatment-understanding/2462223/A new study published in the Journal of Drugs in Dermatology offers a glimp
- Long-Term Analysis Shows Upadacitinib Safe Up to 5 Years for Moderate to Severe ADhttps://practicaldermatology.com/news/long-term-analysis-shows-upadacitinib-safe-up-to-5-years-for-moderate-to-severe-ad/2462222/Upadacitinib for the treatment of moderate-to-severe atopic dermatitis (AD) was shown to have an acceptable safety profile at 5 years, according to a new integrated analysis.
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- Upadacitinib Improves Night-time Itch and Sleep Disturbance: Studyhttps://practicaldermatology.com/news/analysis-upadacitinib-improves-night-time-itch-and-sleep-disturbance/2462217/Researchers publishing the poster at Maui Derm 2024 analyzed integrated data from the Measure Up 1 and Measure Up 2 phase-3 randomized, double-blinded studies looking the safety and efficacy of upadacitinib 15 mg (UPA 1
- FDA Gives Nod to Marketing DermaSensor for Skin Lesion Evaluationhttps://practicaldermatology.com/news/fda-gives-nod-to-dermasensor-for-skin-lesion-evaluation/2462213/The U.S Food and Drug Administration (FDA) announced that it has granted authorization for marketing for the DermaSensor (DermaSensor Inc.) prescription device, indicated for the evaluation of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients ag
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeuti
- Upadacitinib in Atopic Dermatitis: New Safety Data Encourages Practitioners and Patientshttps://practicaldermatology.com/news/long-term-safety-of-upadacitinib-in-atopic-dermatitis-5-year-analysis-unveils-encouraging-results/2462210/A recent analysis reveals that upadacitinib, an oral Janus kinase 1 (JAK1) inhibitor, maintains its safety profile over a span of 5 years, aiding individuals
- Skin Deep Solutions: Navigating Acne and Rosacea with Quality Skin Carehttps://practicaldermatology.com/news/skin-deep-solutions-navigating-acne-and-rosacea-with-quality-skin-care/2462209/In the ever-evolving landscape of dermatology, Hilary Baldwin, MD, a board-certified dermatologist, and the medical director of the Acne Treatment & Research Center in Brooklyn, recently shed light on the critical role
- Study: Transgender Individuals Experience Stigma, Treatment Barriershttps://practicaldermatology.com/news/lived-experience-of-acne-and-acne-treatment-in-transgender-patients/2462206/New research sheds light on the lived experiences of transgender individuals who have acne. "While acne is common in transgender and gender-diverse people and is associated with gender-affirming hormone therapy, little research has examined these factors and their impact in g